Dicerna gets FDA orphan drug designation for alpha-1 antitrypsin deficiency drug candidate


Dicerna Pharma (NASDAQ:DRNA) received FDA orphan drug designation for DCR-A1AT for the treatment of alpha-1 antitrypsin deficiency, a genetic disorder that can cause lung and liver disease.

The company submitted a clinical trial application in June 2019 to the Swedish Medical Products Agency for DCR-A1AT, a ribonucleic acid interference, or RNAi, therapeutic. Dicerna began enrolling healthy volunteers in a Phase 1/2 trial in late 2019 and expects to dose the first patient in the second half of 2020.

“RNAi technology has shown significant potential in the treatment of liver-related diseases, and we look forward to continuing to investigate DCR-A1AT’s potential to make a meaningful difference for this underserved patient population,” Dr. Ralf Rosskamp, Dicerna’s CMO, said in a statement.

The European Commission granted orphan drug designation to DCR-A1AT in December 2019 for the same indication.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.